HALO vs. CBPO, MNTA, IOVA, TWST, NVAX, ALNY, NBIX, BMRN, INCY, and UTHR
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), Novavax (NVAX), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
Halozyme Therapeutics (NASDAQ:HALO) and China Biologic Products (NASDAQ:CBPO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations.
Halozyme Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
Halozyme Therapeutics received 152 more outperform votes than China Biologic Products when rated by MarketBeat users. Likewise, 69.19% of users gave Halozyme Therapeutics an outperform vote while only 60.21% of users gave China Biologic Products an outperform vote.
Halozyme Therapeutics presently has a consensus target price of $53.14, suggesting a potential upside of 19.99%. Given Halozyme Therapeutics' higher possible upside, equities research analysts clearly believe Halozyme Therapeutics is more favorable than China Biologic Products.
Halozyme Therapeutics has higher revenue and earnings than China Biologic Products. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics has a net margin of 36.94% compared to China Biologic Products' net margin of 27.43%. Halozyme Therapeutics' return on equity of 225.71% beat China Biologic Products' return on equity.
97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 34.8% of China Biologic Products shares are held by institutional investors. 2.4% of Halozyme Therapeutics shares are held by insiders. Comparatively, 2.7% of China Biologic Products shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Halozyme Therapeutics had 7 more articles in the media than China Biologic Products. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 0 mentions for China Biologic Products. Halozyme Therapeutics' average media sentiment score of 1.35 beat China Biologic Products' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Summary
Halozyme Therapeutics beats China Biologic Products on 13 of the 17 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
